PBMWW: Psyence Biomedical Ltd. Warrant Stocks News on July 27, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

PBMWW

GlobeNewswire

11 hours ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

PBMWW

GlobeNewswire

2 days ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

US home sales dip, Secret Service director resigns: Catalysts

PBMWW

Yahoo Finance Video

3 days ago

US home sales dip, Secret Service director resigns: Catalysts

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

PBMWW

GlobeNewswire

23 days ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

PBMWW

GlobeNewswire

2 months ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

PBMWW

GlobeNewswire

3 months ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

PBMWW

GlobeNewswire

3 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

PBMWW

GlobeNewswire

4 months ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

PBMWW

GlobeNewswire

4 months ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

PBMWW

GlobeNewswire

4 months ago

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

PBMWW

GlobeNewswire

4 months ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

PBMWW

GlobeNewswire

4 months ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

PBMWW

GlobeNewswire

5 months ago

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

PBMWW

GlobeNewswire

5 months ago

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

PBMWW

GlobeNewswire

5 months ago

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

PBMWW

Business Wire

6 months ago

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

King Charles III spends third day in London hospital after prostate surgery

PBMWW

AFP

6 months ago

King Charles III spends third day in London hospital after prostate surgery

Whether or not the Fed cuts rates is not the right question

PBMWW

Yahoo Finance

6 months ago

Whether or not the Fed cuts rates is not the right question

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

PBMWW

GlobeNewswire

6 months ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

PBMWW

GlobeNewswire

7 months ago

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Banzai Executes LOI to Acquire Top Rated Lead Generation Platform, IGLeads

PBMWW

GlobeNewswire

7 months ago

Banzai Executes LOI to Acquire Top Rated Lead Generation Platform, IGLeads

SYLA’s Rimawari-kun Platform’s Gross Merchandise Value Surpasses Five Billion Yen

PBMWW

GlobeNewswire

7 months ago

SYLA’s Rimawari-kun Platform’s Gross Merchandise Value Surpasses Five Billion Yen

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

PBMWW

Simply Wall St.

7 months ago

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

Arqit Quantum Inc. Announces Financial and Operational Results for the Fiscal Year 2023

PBMWW

GlobeNewswire

8 months ago

Arqit Quantum Inc. Announces Financial and Operational Results for the Fiscal Year 2023

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

PBMWW

Simply Wall St.

8 months ago

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

PBMWW

GlobeNewswire

8 months ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

PBMWW

GlobeNewswire

8 months ago

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

trivago (NASDAQ:TRVG) Is Doing The Right Things To Multiply Its Share Price

PBMWW

Simply Wall St.

8 months ago

trivago (NASDAQ:TRVG) Is Doing The Right Things To Multiply Its Share Price

FG Group Holdings Reports Third Quarter 2023 Operating Results

PBMWW

GlobeNewswire

9 months ago

FG Group Holdings Reports Third Quarter 2023 Operating Results

Cue Health Inc. (NASDAQ:HLTH) Q3 2023 Earnings Call Transcript

PBMWW

Insider Monkey

9 months ago

Cue Health Inc. (NASDAQ:HLTH) Q3 2023 Earnings Call Transcript

PBMWW

Business Wire

9 months ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

PBMWW

Business Wire

9 months ago

CuriosityStream To Report Third Quarter 2023 Financial Results on November 9, 2023

PBMWW

Associated Press Finance

9 months ago

Cherry Hill: Q3 Earnings Snapshot

PBMWW

GuruFocus.com

9 months ago

Latest Psyence Biomedical Ltd. Warrant (PBMWW) News on July 27, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

US home sales dip, Secret Service director resigns: Catalysts

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Tivic Enters Exclusive Distribution Agreement with Top 10 Medical Product Distributor for Mass Market Retail

King Charles III spends third day in London hospital after prostate surgery

Whether or not the Fed cuts rates is not the right question

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Banzai Executes LOI to Acquire Top Rated Lead Generation Platform, IGLeads

SYLA’s Rimawari-kun Platform’s Gross Merchandise Value Surpasses Five Billion Yen

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

Arqit Quantum Inc. Announces Financial and Operational Results for the Fiscal Year 2023

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

trivago (NASDAQ:TRVG) Is Doing The Right Things To Multiply Its Share Price

FG Group Holdings Reports Third Quarter 2023 Operating Results

Cue Health Inc. (NASDAQ:HLTH) Q3 2023 Earnings Call Transcript

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

CuriosityStream To Report Third Quarter 2023 Financial Results on November 9, 2023

Cherry Hill: Q3 Earnings Snapshot

Cherry Hill Mortgage Investment Corp (CHMI) Reports Q3 2023 Earnings: Net Income Rises to $13. ...

Share on Social Networks: